SG165178A1 - Novel composition comprising rosiglitazone and another antidiabetic agent - Google Patents

Novel composition comprising rosiglitazone and another antidiabetic agent

Info

Publication number
SG165178A1
SG165178A1 SG200901679-1A SG2009016791A SG165178A1 SG 165178 A1 SG165178 A1 SG 165178A1 SG 2009016791 A SG2009016791 A SG 2009016791A SG 165178 A1 SG165178 A1 SG 165178A1
Authority
SG
Singapore
Prior art keywords
rosiglitazone
antidiabetic agent
novel composition
another antidiabetic
dosage form
Prior art date
Application number
SG200901679-1A
Other languages
English (en)
Inventor
Peter John Coles
Donald Colin Mackenzie
Paul Norman Jnr Mudd
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG165178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of SG165178A1 publication Critical patent/SG165178A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200901679-1A 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent SG165178A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition

Publications (1)

Publication Number Publication Date
SG165178A1 true SG165178A1 (en) 2010-10-28

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200901679-1A SG165178A1 (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent

Country Status (37)

Country Link
US (1) US20080206336A1 (pt)
EP (1) EP1663191B1 (pt)
JP (1) JP4714147B2 (pt)
KR (1) KR20060071396A (pt)
CN (2) CN1835741B (pt)
AP (1) AP2006003489A0 (pt)
AR (1) AR045230A1 (pt)
AT (1) ATE455542T1 (pt)
AU (1) AU2004262933B2 (pt)
BR (1) BRPI0413419A (pt)
CA (1) CA2534480A1 (pt)
CY (1) CY1109923T1 (pt)
DE (1) DE602004025257D1 (pt)
DK (1) DK1663191T3 (pt)
EA (2) EA200800966A1 (pt)
EC (1) ECSP066338A (pt)
ES (1) ES2339554T3 (pt)
GB (1) GB0318824D0 (pt)
HK (1) HK1092051A1 (pt)
HR (1) HRP20100160T1 (pt)
IL (1) IL173177A0 (pt)
IS (1) IS2745B (pt)
MA (1) MA27996A1 (pt)
MX (1) MXPA06001629A (pt)
MY (1) MY151053A (pt)
NO (1) NO20061161L (pt)
NZ (1) NZ544632A (pt)
OA (1) OA13233A (pt)
PE (1) PE20050357A1 (pt)
PL (1) PL1663191T3 (pt)
PT (1) PT1663191E (pt)
SG (1) SG165178A1 (pt)
SI (1) SI1663191T1 (pt)
TW (1) TW200517146A (pt)
UA (1) UA82537C2 (pt)
UY (1) UY28461A1 (pt)
WO (1) WO2005013956A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
KR20110052641A (ko) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 변형 방출형 제형 및 이의 이용 방법
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
WO2012006398A2 (en) * 2010-07-09 2012-01-12 Bhv Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
DE69833179T2 (de) * 1998-11-10 2006-09-07 The Procter & Gamble Company, Cincinnati Bleichmittelzusammensetzungen
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
ES2290130T3 (es) * 2000-05-01 2008-02-16 Aeropharm Technology, Llc Formulacion de nucleo.
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
ATE455542T1 (de) 2010-02-15
UA82537C2 (uk) 2008-04-25
EP1663191A1 (en) 2006-06-07
BRPI0413419A (pt) 2006-10-10
KR20060071396A (ko) 2006-06-26
CA2534480A1 (en) 2005-02-17
WO2005013956A1 (en) 2005-02-17
MY151053A (en) 2014-03-31
MXPA06001629A (es) 2006-04-28
DE602004025257D1 (de) 2010-03-11
US20080206336A1 (en) 2008-08-28
EA011550B1 (ru) 2009-04-28
JP4714147B2 (ja) 2011-06-29
EP1663191B1 (en) 2010-01-20
CN1835741A (zh) 2006-09-20
UY28461A1 (es) 2005-03-31
IS2745B (is) 2011-08-15
GB0318824D0 (en) 2003-09-10
IS8337A (is) 2006-03-02
AP2006003489A0 (en) 2006-02-28
AU2004262933B2 (en) 2009-12-10
HK1092051A1 (en) 2007-02-02
EA200800966A1 (ru) 2009-04-28
CY1109923T1 (el) 2014-09-10
ES2339554T3 (es) 2010-05-21
AR045230A1 (es) 2005-10-19
ECSP066338A (es) 2006-07-28
NO20061161L (no) 2006-03-10
IL173177A0 (en) 2006-06-11
EA200600400A1 (ru) 2006-08-25
PE20050357A1 (es) 2005-06-01
OA13233A (en) 2006-12-13
DK1663191T3 (da) 2010-04-26
JP2007501830A (ja) 2007-02-01
MA27996A1 (fr) 2006-07-03
TW200517146A (en) 2005-06-01
NZ544632A (en) 2009-03-31
HRP20100160T1 (hr) 2010-05-31
PT1663191E (pt) 2010-03-16
SI1663191T1 (sl) 2010-05-31
CN102397551A (zh) 2012-04-04
CN1835741B (zh) 2011-12-14
PL1663191T3 (pl) 2010-06-30
AU2004262933A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2006063841A3 (en) Trycyclic heterocycles, their manufacture and use as pharmaceutical agents
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
GR3035415T3 (en) Oral pharmaceutical compositions for specific colon delivery.
HUP0400333A3 (en) Crystalline anticholinergic, method for its production, and use thereof in the production of pharmaceutical composition
ME00318B (me) Nova kompozicija i njena upotreba
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
HUP0401224A3 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
DE602004011966D1 (en) Heterocyclylverbindungen
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
SG165178A1 (en) Novel composition comprising rosiglitazone and another antidiabetic agent
IL166596A0 (en) Salt of morphine-6-glucoronide
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
AP1736A (en) Oral dosage form for controlled drug release.
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
WO2005044222A3 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
TW200510370A (en) Urea derivatives
WO2003080617A8 (en) Pyrazolopyrimidine derivatives
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
WO2005016921A3 (en) Novel oxazoles, their manufacture and use as pharmaceutical agents